These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29109164)

  • 1. Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.
    Pires de Mello CP; Tao X; Kim TH; Bulitta JB; Rodriquez JL; Pomeroy JJ; Brown AN
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model.
    Pires de Mello CP; Tao X; Kim TH; Vicchiarelli M; Bulitta JB; Kaushik A; Brown AN
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models.
    Kim JA; Seong RK; Kumar M; Shin OS
    Viruses; 2018 Feb; 10(2):. PubMed ID: 29425176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines.
    Franco EJ; Rodriquez JL; Pomeroy JJ; Hanrahan KC; Brown AN
    Antivir Chem Chemother; 2018; 26():2040206618807580. PubMed ID: 30354193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication.
    Cai L; Sun Y; Song Y; Xu L; Bei Z; Zhang D; Dou Y; Wang H
    Arch Virol; 2017 Sep; 162(9):2847-2853. PubMed ID: 28597088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extinction of Zika Virus and Usutu Virus by Lethal Mutagenesis Reveals Different Patterns of Sensitivity to Three Mutagenic Drugs.
    Bassi MR; Sempere RN; Meyn P; Polacek C; Arias A
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM).
    Pires de Mello CP; Drusano GL; Rodriquez JL; Kaushik A; Brown AN
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29890736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice.
    Kamiyama N; Soma R; Hidano S; Watanabe K; Umekita H; Fukuda C; Noguchi K; Gendo Y; Ozaki T; Sonoda A; Sachi N; Runtuwene LR; Miura Y; Matsubara E; Tajima S; Takasaki T; Eshita Y; Kobayashi T
    Antiviral Res; 2017 Oct; 146():1-11. PubMed ID: 28818572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro.
    Vicenti I; Boccuto A; Giannini A; Dragoni F; Saladini F; Zazzi M
    Virus Res; 2018 Jan; 244():64-70. PubMed ID: 29113824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.
    Gallegos KM; Drusano GL; D Argenio DZ; Brown AN
    J Infect Dis; 2016 Oct; 214(8):1192-7. PubMed ID: 27496974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines.
    Franco EJ; Tao X; Hanrahan KC; Zhou J; Bulitta JB; Brown AN
    Microorganisms; 2021 Feb; 9(2):. PubMed ID: 33540830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus.
    Franco EJ; Pires de Mello CP; Brown AN
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33925551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Congenital Zika Disease Depend on Timing of Infection and Maternal-Fetal Interferon Action.
    Chen J; Liang Y; Yi P; Xu L; Hawkins HK; Rossi SL; Soong L; Cai J; Menon R; Sun J
    Cell Rep; 2017 Nov; 21(6):1588-1599. PubMed ID: 29117563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin.
    Baz M; Goyette N; Griffin BD; Kobinger GP; Boivin G
    Antivir Ther; 2017; 22(7):613-618. PubMed ID: 28694390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals.
    Lanko K; Eggermont K; Patel A; Kaptein S; Delang L; Verfaillie CM; Neyts J
    Antiviral Res; 2017 Sep; 145():82-86. PubMed ID: 28736077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antiviral activity of Sofosbuvir and type-I interferons (α and β) against Zika virus.
    Snyder B; Goebel S; Koide F; Ptak R; Kalkeri R
    J Med Virol; 2018 Jan; 90(1):8-12. PubMed ID: 28851097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay.
    Adcock RS; Chu YK; Golden JE; Chung DH
    Antiviral Res; 2017 Feb; 138():47-56. PubMed ID: 27919709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening.
    Pattnaik A; Palermo N; Sahoo BR; Yuan Z; Hu D; Annamalai AS; Vu HLX; Correas I; Prathipati PK; Destache CJ; Li Q; Osorio FA; Pattnaik AK; Xiang SH
    Antiviral Res; 2018 Mar; 151():78-86. PubMed ID: 29274845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model.
    Zmurko J; Marques RE; Schols D; Verbeken E; Kaptein SJ; Neyts J
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004695. PubMed ID: 27163257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens.
    Tong X; Smith J; Bukreyeva N; Koma T; Manning JT; Kalkeri R; Kwong AD; Paessler S
    Antiviral Res; 2018 Jan; 149():34-40. PubMed ID: 29126899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.